Full Length Research Paper
References
|
Anta L, Llibre JM, Poveda E, Blanco JL, Álvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, De Mendoza C, Iribarren JA, Gatell JM, Ribera E, Martínez-Picado J, Clotet B, Jaén A, Dalmau D, Peraire J, Vidal F, Gómez-Sirvent JL (2013). Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 27(1):81-85. |
|
|
Arts EJ, Hazuda DJ (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine 2(4):a007161. |
|
|
Aung ZZ, Oo MM, Tripathy JP, Kyaw NTT, Hone S, Oo HN, Majumdar SS (2018). Are death and loss to follow-up still high in people living with HIV on ART after national scale-up and earlier treatment initiation? A large cohort study in government hospitalbased setting, Myanmar: 2013-2016. PLoS ONE 13(9):1-15. |
|
|
Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH (2020). Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Current HIV/AIDS Reports 17(3):249-258. |
|
|
Brault MA, Spiegelman D, Hargreaves J, Nash D, Vermund SH (2019). Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence. Journal of Acquired Immune Deficiency Syndromes 82(2):S104-S112. |
|
|
Crawford KW, Njeru D, Maswai J, Omondi M, Apollo D, Kimetto J, Gitonga L, Munyao J, Langat R, Aoko A, Tarus J, Khamadi S, Hamm TE (2014). Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy. AIDS 28(3):442-445. |
|
|
de Waal R, Lessells R, Hauser A, Kouyos R, Davies MA, Egger M, Wandeler G (2018). HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication 4(Suppl 2):55-58. |
|
|
Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M (2018). Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 subtype C-infected patients failing nevirapine or efavirenz-based combination antiretroviral therapy in botswana. AIDS Research and Human Retroviruses 34(8):667-671. |
|
|
Dokubo EK, Baddeley A, Pathmanathan I, Coggin W, Firth J, Getahun H, Kaplan J, Date A (2014). Provision of antiretroviral therapy for HIV-positive TB patients - 19 countries, sub-saharan Africa, 2009-2013. Morbidity and Mortality Weekly Report 63(47):1104-1107. |
|
|
Eakle R, Venter F, Rees H (2018). Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? Retrovirology 15:29 (2018). |
|
|
Echagüen, AO, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D, Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team (2005). Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 19(13):1385-1391. |
|
|
Faria NR, Vidal N, Lourenco J, Raghwani J, Sigaloff KCE, Tatem AJ, Van De Vijver DAM, Pineda-Peña AC, Rose R, Wallis CL, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Muwonga J, Suchard MA, De Wit TFR, Hamers RL, Ndembi N, Baele G, Peeters M, Dellicour S (2019). Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa. PLoS Pathogens 15(12):e1007976. |
|
|
Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C (2015). Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Journal of Antimicrobial Chemotherapy 70(2):562-565. |
|
|
Girum T, Wasie A, Worku A (2018). Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: A time series analysis. BMC Infectious Diseases 18(1):1-10. |
|
|
Junqueira DM, de Matos Almeida SE (2016). HIV-1 subtype B: Traces of a pandemic. Virology 495:173-184. |
|
|
Kantor R, DeLong A, Balamane M, Schreier L, Lloyd RM, Injera W, Kamle L, Mambo F, Muyonga S, Katzenstein D, Hogan J, Buziba N, Diero L (2014). HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya. Journal of the International AIDS Society 17(1):19262. |
|
|
Kenya AIDS Response Progress Report (2016). Country progress report-Kenya Global AIDS Monitoring 2017. |
|
|
Kharsany ABM, Karim QA (2016). HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. The Open AIDS Journal 10(1):34-48. |
|
|
Kimanga DO, Ogola S, Umuro, Ng?ang?a A, Kimondo L, Murithi P, Muttunga J, Waruiru W, Mohammed I, Sharrif S, De Cock KM, Kim AA (2014). Prevalence and incidence of HIV infection, trends, and risk factors among persons aged 15-64 years in Kenya. Journal of Acquired Immune Deficiency Syndromes 66 Suppl 1(Suppl 1):S13-26. |
|
|
Lahuerta M, Syowai M, Vakil S, Odhiambo J, Gitonga M, Sugandhi N, Odhiambo S, Kimani M, Wamicwe J, Batuka J, Imbuki E, Bartilol K, Abrams EJ (2020). Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya. PLoS ONE 15(4):e0232104. |
|
|
Lessells RJ, Katzenstein DK, De Oliveira T (2012). Are subtype differences important in HIV drug resistance? Current Opinion in Virology 2(5):636-643. |
|
|
Mabaso M, Makola L, Naidoo I, Mlangeni LL, Jooste S, Simbayi L (2019). HIV prevalence in South Africa through gender and racial lenses: results from the 2012 population-based national household survey. International Journal for Equity in Health 18(1):1-11. |
|
|
Marsh K, Eaton JW, Mahy M, Sabin K, Autenrieth CS, Wanyeki I, Daher J, Ghys PD (2019). Global, regional and country-level 90-90-90 estimates for 2018. AIDS 15;33 Suppl 3(Suppl 3):S213-S226. |
|
|
Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P (2014). Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and hiv transmission: The "HIV treatment as prevention" experience in a Canadian setting. PLoS ONE 9(2):1-10. |
|
|
Mwau M, Syeunda CA, Adhiambo M, Bwana P, Kithinji L, Mwende J, Oyiengo L, Sirengo M, Boeke CE (2018). Scale-up of Kenya's national HIV viral load program: Findings and lessons learned. PLoS ONE 13(1):e0190659. |
|
|
National AIDS and STI Control Programme (2018). Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya. |
|
|
National AIDS Control Council (2018). Kenya HIV Estimates Report 2018. |
|
|
National AIDS Control Council (2016). Kenya HIV County Profiles 2016. NACC, Ministry of Health, Government of Kenya. |
|
|
Ndashimye E, Arts EJ (2019). The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. Infectious Diseases of Poverty 8(1):63. |
|
|
Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, Kruger J, Govender NP, Boulle A (2018). The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clinical Infectious Diseases 66:S118-S125. |
|
|
Paul NI, Ugwu RO (2020). Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria. Journal of Scientific Research and Reports 26(2):52-59. |
|
|
Qiagen (2020). QIAamp® Viral RNA Mini Handbook. |
|
|
Saravanan S, Kausalya B, Gomathi S, Sivamalar S, Pachamuthu B, Selvamuthu P, Pradeep A, Sunil S, Mothi SN, Smith DM, Kantor R (2017). Etravirine and rilpivirine drug resistance among HIV-1 subtype C infected children failing non-nucleoside reverse transcriptase inhibitor-based regimens in South India. AIDS Research and Human Retroviruses 26(2):52-59. |
|
|
Shao Y, Williamson C (2012). The HIV-1 epidemic: Low- to middle-income countries. Cold Spring Harbor Perspectives in Medicine 2(3):a007187. |
|
|
Sluis-Cremer N (2014). The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses 6(8):2960-2973. |
|
|
Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A (2017). Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS ONE 12(6):e0178942. |
|
|
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008). The challenge of HIV-1 subtype diversity. New England Journal of Medicine 358(15):1590-1602. |
|
|
Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, Putcharoen O (2016). Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study. PloS One 11(4):e0154221. |
|
|
Teeranaipong P, Sirivichayakul S, Mekprasan S, Ruxrungtham K, Putcharoen O (2014). Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand. Journal of the International AIDS Society 17(4 Suppl 3):19740. |
|
|
Joint United Nations Programme on HIV/AIDS (2018a). 90-90-90: treatment for all | UNAIDS. Miles To Go - UNAIDS Data 2018. |
|
|
Joint United Nations Programme on HIV/AIDS (2018b). KENYA | 2018. Country Factsheets. |
|
|
Joint United Nations Programme on HIV/AIDS (2018c). UNAIDS Data 2018. |
|
|
Joint United Nations Programme on HIV/AIDS (2019). Fact Sheet - Global AIDS Update 2019, 2018 Global HIV Statistics. |
|
|
Usach I, Melis V, Peris JE (2013). Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability. Journal of the International AIDS Society 16(1):1-14. |
|
|
Vandormael A, Akullian A, Siedner M, de Oliveira T, Bärnighausen T, Tanser F (2019). Declines in HIV incidence among men and women in a South African population-based cohort. Nature Communications. 10(1):1-10. |
|
|
Vardell E (2020). Global Health Observatory Data Repository. Medical Reference Services Quarterly 39(1):67-74 |
|
|
Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen PL, Rwambuya S, Munjoma M, Chipato T, Byamugisha J, Van Der Pol B, Mugyenyi P, Salata RA, Morrison CS, Arts EJ (2016). Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. EBioMedicine 13:305-314. |
|
|
Vitoria M, Rangaraj A, Ford N, Doherty M (2019). Current and future priorities for the development of optimal HIV drugs. Current Opinion in HIV and AIDS 14(2):143-149. |
|
|
World Health Organisation (WHO) (2019). Policy Brief: Update of Recommendations on First-and Second-Line Antiretroviral Regimens. WHO Library Cataloguing-in-Publication Data. |
|
|
Zhou Y, Lu J, Wang J, Yan H, Li J, Xu X, Zhang Z, Qiu T, Ding P, Fu G, Huan X, Hu H (2016). Prevalence of HIV antiretroviral drug resistance and Its Impacts on HIV-1 virological failures in Jiangsu, China: A Cross-Sectional Study. BioMed Research International 2016:1752437. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
